<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04668716</url>
  </required_header>
  <id_info>
    <org_study_id>20NM35</org_study_id>
    <nct_id>NCT04668716</nct_id>
  </id_info>
  <brief_title>Brain Involvement in Dystrophinopathies Part 2</brief_title>
  <official_title>Brain INvolvement in Dystrophinopathies (BIND): Deep Functional Phenotyping of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy Patients (WP5 and WP6) Part 2: a Neurobehavioural and MRI Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College London Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Newcastle-upon-Tyne Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stichting Kempenhaeghe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Region Hovedstadens Apotek</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Necker Enfants Malades</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Università degli Studi di Ferrara</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad Complutense de Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College London Hospitals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to understand the relationship between DMD and BMD brain&#xD;
      comorbidities, and the location of the gene mutation which causes the disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intellectual disability and neurobehavioural comorbidities affect at least 50% of the&#xD;
      individuals with Duchenne muscular dystrophy (DMD) which, although a rare genetic disease, is&#xD;
      the most common form of muscular dystrophy in childhood. Several studies have documented that&#xD;
      25% of the DMD population has intellectual disability with recent studies suggesting that&#xD;
      autism and clinically relevant hyperactivity affects 20% and 25% of DMD boys respectively. A&#xD;
      milder allelic variant, named Becker muscular dystrophy (BMD), has similar prevalence in the&#xD;
      population and is also associated with variable degrees of central nervous system (CNS)&#xD;
      comorbidities, which however have been less well defined.&#xD;
&#xD;
      We will address this knowledge gap in a large multicentre study funded by the European&#xD;
      Commission H2020 programme, involving 6 countries (Denmark; The Netherlands; France; Spain;&#xD;
      Italy and UK) with the largest European neuromuscular centres and advocacy groups. The aim&#xD;
      will be to study the neurobehavioural aspects of DMD and BMD as well as their correlation to&#xD;
      the genotype.&#xD;
&#xD;
      This study will involve male participants with DMD aged 5-17 years and with BMD aged 5-50&#xD;
      years, who will complete a battery of cognitive and behavioural assessments. The objective of&#xD;
      this study is to deep phenotype a cohort of 270 individuals with DMD and BMD, focussing on&#xD;
      the cognitive and neurobehavioural aspects of these conditions. A sub-groups of patients will&#xD;
      also undergo magnetic resonance imaging to investigate brain structure, volumetric features,&#xD;
      perfusion, functional connectivity and metabolism. This information will then be correlated&#xD;
      to the location of the underlying DMD gene mutation. The brain imaging part is also going to&#xD;
      involve age and sex-matched controls.&#xD;
&#xD;
      While there have been major improvement on the definition of the genetic basis of the&#xD;
      skeletal aspects of dystrophinopathies and their correlation to the DMD genotype, our&#xD;
      knowledge on the spectrum of lifespan CNS comorbidities and the precise genotype / phenotype&#xD;
      correlations in patients with different DMD mutations is still limited. A study looking into&#xD;
      the association between different dystrophin isoforms and different CNS manifestations would&#xD;
      therefore offer a unique opportunity to unravel the role of specific dystrophin isoforms and&#xD;
      the associated circuitries in brain function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CNS Comorbidity Phenotyping</measure>
    <time_frame>170 minutes</time_frame>
    <description>Correlate CNS comorbidity phenotypes with genotype in DMD and BMD patients</description>
  </primary_outcome>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <condition>Becker Muscular Dystrophy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The investigators will recruit both patients who have completed a related online study&#xD;
        (ClinicalTrials.gov Identifier NCT04583917) and patients directly recruited from&#xD;
        participating clinics or research settings. These patients will undergo a structured&#xD;
        cognitive and neurobehavioural assessment. A subgroup of patients assessed in the research&#xD;
        setting will be invited to also attend a second visit involving a magnetic resonance&#xD;
        imaging (MRI) scan of the brain.&#xD;
&#xD;
        The investigators aim to recruit 80 participants in the UK and the number of participants&#xD;
        in the remaining countries will be 190 patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For DMD patients:&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  age 5-17 years&#xD;
&#xD;
          -  genetically-proven diagnosis of DMD&#xD;
&#xD;
          -  genetic mutation that abrogates expression of Dp427 alone (assigned in DMD Group 1:&#xD;
             Dp427-/Dp140+) or both Dp427 and Dp140 (assigned to DMD Group 2: Dp427-/Dp140-); or&#xD;
             all isoforms (assigned to DMD group 3)&#xD;
&#xD;
        For BMD patients:&#xD;
&#xD;
          -  age 5-50 years&#xD;
&#xD;
          -  genetically-proven diagnosis of BMD&#xD;
&#xD;
          -  genetic mutation that decreases expression of Dp427 alone (assigned to BMD Group 1),&#xD;
             of both Dp427 and Dp140 (assigned to BMD Group 2), or of all the isoforms (assigned to&#xD;
             BMD group 3).&#xD;
&#xD;
        For MRI controls:&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  age 5-50 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For DMD and BMD patients:&#xD;
&#xD;
          -  Lack of a molecular diagnosis of DMD or BMD&#xD;
&#xD;
          -  Mutation falls outside the regions of interest&#xD;
&#xD;
          -  A severe co-morbidity or planned surgical intervention within 6 months from the study&#xD;
             which could interfere with the well-being of the participant&#xD;
&#xD;
        For MRI controls:&#xD;
&#xD;
          -  any muscle disease&#xD;
&#xD;
          -  a brain disorder (such as severe brain concussion in past history, congenital brain&#xD;
             anomalies, epilepsy)&#xD;
&#xD;
        General exclusion criteria for MRI:&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Pacemakers and defibrillators&#xD;
&#xD;
          -  Nerve stimulators&#xD;
&#xD;
          -  Intracranial clips&#xD;
&#xD;
          -  Intraorbital or intraocular metallic fragments&#xD;
&#xD;
          -  Cochlear implants&#xD;
&#xD;
          -  Ferromagnetic implants (e.g. thoracic implant for scoliosis)&#xD;
&#xD;
          -  Inability to lie supine during less than 45 minutes&#xD;
&#xD;
          -  not having a general practitioner&#xD;
&#xD;
          -  severe learning disability which will require a general anaesthetic&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>DMD and BMD are sex-linked conditions, which occur predominantly in males.</gender_description>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://bindproject.eu/</url>
    <description>BIND: Brain Involvement in Dystrophinopathies study website</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University College London Hospitals</investigator_affiliation>
    <investigator_full_name>Professor Francesco Muntoni</investigator_full_name>
    <investigator_title>Chair of Paediatric Neurology</investigator_title>
  </responsible_party>
  <keyword>Duchenne Muscular Dystrophy</keyword>
  <keyword>Deep phenotyping</keyword>
  <keyword>Gene therapies</keyword>
  <keyword>Learning difficulties and autism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

